Cryoport Inc
Change company Symbol lookup
Select an option...
CYRX Cryoport Inc
GRPN Groupon Inc
AINV Apollo Investment Corp
NVRO Nevro Corp
MSFT Microsoft Corp
RLGMF West Red Lake Gold Mines Inc
FF FutureFuel Corp
TRP TC Energy Corp
EQC Equity Commonwealth
$ETINV Refinitiv Belgium Investment Managem
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

Cryoport, Inc. (Cryoport), is a life sciences services company that is an integral part of the supply chain supporting the biopharma, reproductive medicine and animal health markets. Through its products and services the Company enable its clients to ship, store and deliver cellular-based materials and drug products as well as other life sciences commodities in a precise, defined temperature-controlled state. The Company’s advanced platform is comprised of comprehensive and technology-centric systems and solutions are designed to support the global high-volume distribution of commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA) and other international regulatory bodies for distribution in the Americas, Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC) regions.

Closing Price
$47.34
Day's Change
-1.63 (-3.33%)
Bid
--
Ask
--
B/A Size
--
Day's High
49.89
Day's Low
46.95
Volume
(Below Average)
Volume:
631,659

10-day average volume:
754,427
631,659

Company Profile

Cryoport, Inc. (Cryoport), is a life sciences services company that is an integral part of the supply chain supporting the biopharma, reproductive medicine and animal health markets. Through its products and services the Company enable its clients to ship, store and deliver cellular-based materials and drug products as well as other life sciences commodities in a precise, defined temperature-controlled state. The Company’s advanced platform is comprised of comprehensive and technology-centric systems and solutions are designed to support the global high-volume distribution of commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA) and other international regulatory bodies for distribution in the Americas, Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC) regions.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
52.38x
Price/Book (MRQ)
16.98x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2020
Current Month
7.7M
Previous Month
7.6M
Percent of Float
19.59%
Days to Cover
9.8596 Days

Share Information

CYRX is in a share class of common stock
Float
39.2M
Shares Outstanding
39.7M
Institutions Holding Shares
235
93.85%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Jerrell Wilson SheltonChmn.
  • Robert S. StefanovichCFO
  • Richard J. Berman
  • Daniel M. HancockDir.
  • Ram M. JagannathDir.

Address

Insider Trading

During the most recent quarter, 31K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.